Anti-PD1 rechallenge in combination with anti-angiogenesis or anti-EGFR treatment beyond progression in recurrent/metastatic nasopharyngeal carcinoma patients
We aim to evaluate the efficacy and safety of anti-PD1 rechallenge in combination with anti-angiogenesis or anti-EGFR treatment in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC) patients who progressed to previous anti-PD1 therapy. Enrolled patients were divided into a combination group and...
Gespeichert in:
| Veröffentlicht in: | Critical reviews in oncology/hematology 2023-10, Vol.190, p.104113, Article 104113 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | 104113 |
| container_title | Critical reviews in oncology/hematology |
| container_volume | 190 |
| creator | Jiang, Yaofei Fang, Ting Lu, Nian Bei, Weixin Dong, Shuhui Xia, Weixiong Liang, Hu Xiang, Yanqun |
| description | We aim to evaluate the efficacy and safety of anti-PD1 rechallenge in combination with anti-angiogenesis or anti-EGFR treatment in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC) patients who progressed to previous anti-PD1 therapy. Enrolled patients were divided into a combination group and a chemotherapy only group. A total of 145 patients were enrolled. The median progress-free survival (mPFS) was 7.9 months and 4.4 months, respectively for the two groups. The combination group exhibited significantly longer PFS (HR=0.363, p |
| doi_str_mv | 10.1016/j.critrevonc.2023.104113 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2857853320</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1040842823002019</els_id><sourcerecordid>2857853320</sourcerecordid><originalsourceid>FETCH-LOGICAL-c401t-2999eee2702423a32bfc933544e66d41d671b5603b59235131a98c115873793</originalsourceid><addsrcrecordid>eNqFkctOwzAQRSMEElD4By_ZpPiV1xJKeUiVQMDecpxp6yqxi-0W8TN8K1MFiSUrWzN3juf6ZhlhdMooK683UxNsCrD3zkw55QLLkjFxlJ2xumpyKkt2jHcqaV5LXp9m5zFuKKVSltVZ9n3jks1f7hgJYNa678GtgFhHjB9a63Sy3pFPm9ZEH4TaraxfgYNoI_FhLM4f7l8JrqDTAC6RFr6868g2-FWAGA8A5CF-FwL2rwdIOiYkG-J09Nu1Dl_4qO6J0cFY5wdNtthGbbzITpa6j3D5e06yt_v5--wxXzw_PM1uFrmRlKWcN00DALyiXHKhBW-XphGikBLKspOsKyvWFiUVbdFwUTDBdFMbxoq6ElUjJtnVSMWdP3YQkxpsNND32oHfRcXroqoLIThFaT1KTfAxBliqbbADOlCMqkMgaqP-AlGHQNQYCI7ejqOARvYWgooGTRroLH5OUp23_0N-AOYInGY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2857853320</pqid></control><display><type>article</type><title>Anti-PD1 rechallenge in combination with anti-angiogenesis or anti-EGFR treatment beyond progression in recurrent/metastatic nasopharyngeal carcinoma patients</title><source>Elsevier ScienceDirect Journals</source><creator>Jiang, Yaofei ; Fang, Ting ; Lu, Nian ; Bei, Weixin ; Dong, Shuhui ; Xia, Weixiong ; Liang, Hu ; Xiang, Yanqun</creator><creatorcontrib>Jiang, Yaofei ; Fang, Ting ; Lu, Nian ; Bei, Weixin ; Dong, Shuhui ; Xia, Weixiong ; Liang, Hu ; Xiang, Yanqun</creatorcontrib><description>We aim to evaluate the efficacy and safety of anti-PD1 rechallenge in combination with anti-angiogenesis or anti-EGFR treatment in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC) patients who progressed to previous anti-PD1 therapy. Enrolled patients were divided into a combination group and a chemotherapy only group. A total of 145 patients were enrolled. The median progress-free survival (mPFS) was 7.9 months and 4.4 months, respectively for the two groups. The combination group exhibited significantly longer PFS (HR=0.363, p < 0.001), and better disease control ratio (DCR, p = 0.022) compared with the chemotherapy group. Among the combination group, longer PFS was found in those patients who received different PD1 inhibitor from prior therapy, reached object response rate (ORR) from prior anti-PD1 therapy, and EBV DNA ≤ 1500 copy/ml before therapy, comparing to the corresponding other patients. R/M NPC patients who progressed from prior anti-PD1 therapy could benefit from the anti-PD1 rechallenge in combination with anti-angiogenesis or anti-EGFR agents.
[Display omitted]
•R/M NPC patients who progressed from prior anti-PD1 therapy could benefit from the anti-PD1 rechallenge combination therapy.•Adverse reactions of the combination therapy were tolerable.•Those who reached ORR from prior anti-PD1 therapy, EBV DNA ≤ 1500 copy/ml, and got different PD1 inhibitor, benefit more.</description><identifier>ISSN: 1040-8428</identifier><identifier>ISSN: 1879-0461</identifier><identifier>EISSN: 1879-0461</identifier><identifier>DOI: 10.1016/j.critrevonc.2023.104113</identifier><language>eng</language><publisher>Elsevier B.V</publisher><subject>Anti-angiogenesis ; EGFR inhibitors ; Nasopharyngeal carcinoma ; PD1 inhibitors ; Prognosis</subject><ispartof>Critical reviews in oncology/hematology, 2023-10, Vol.190, p.104113, Article 104113</ispartof><rights>2023 The Authors</rights><rights>Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c401t-2999eee2702423a32bfc933544e66d41d671b5603b59235131a98c115873793</citedby><cites>FETCH-LOGICAL-c401t-2999eee2702423a32bfc933544e66d41d671b5603b59235131a98c115873793</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.critrevonc.2023.104113$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,778,782,3539,27907,27908,45978</link.rule.ids></links><search><creatorcontrib>Jiang, Yaofei</creatorcontrib><creatorcontrib>Fang, Ting</creatorcontrib><creatorcontrib>Lu, Nian</creatorcontrib><creatorcontrib>Bei, Weixin</creatorcontrib><creatorcontrib>Dong, Shuhui</creatorcontrib><creatorcontrib>Xia, Weixiong</creatorcontrib><creatorcontrib>Liang, Hu</creatorcontrib><creatorcontrib>Xiang, Yanqun</creatorcontrib><title>Anti-PD1 rechallenge in combination with anti-angiogenesis or anti-EGFR treatment beyond progression in recurrent/metastatic nasopharyngeal carcinoma patients</title><title>Critical reviews in oncology/hematology</title><description>We aim to evaluate the efficacy and safety of anti-PD1 rechallenge in combination with anti-angiogenesis or anti-EGFR treatment in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC) patients who progressed to previous anti-PD1 therapy. Enrolled patients were divided into a combination group and a chemotherapy only group. A total of 145 patients were enrolled. The median progress-free survival (mPFS) was 7.9 months and 4.4 months, respectively for the two groups. The combination group exhibited significantly longer PFS (HR=0.363, p < 0.001), and better disease control ratio (DCR, p = 0.022) compared with the chemotherapy group. Among the combination group, longer PFS was found in those patients who received different PD1 inhibitor from prior therapy, reached object response rate (ORR) from prior anti-PD1 therapy, and EBV DNA ≤ 1500 copy/ml before therapy, comparing to the corresponding other patients. R/M NPC patients who progressed from prior anti-PD1 therapy could benefit from the anti-PD1 rechallenge in combination with anti-angiogenesis or anti-EGFR agents.
[Display omitted]
•R/M NPC patients who progressed from prior anti-PD1 therapy could benefit from the anti-PD1 rechallenge combination therapy.•Adverse reactions of the combination therapy were tolerable.•Those who reached ORR from prior anti-PD1 therapy, EBV DNA ≤ 1500 copy/ml, and got different PD1 inhibitor, benefit more.</description><subject>Anti-angiogenesis</subject><subject>EGFR inhibitors</subject><subject>Nasopharyngeal carcinoma</subject><subject>PD1 inhibitors</subject><subject>Prognosis</subject><issn>1040-8428</issn><issn>1879-0461</issn><issn>1879-0461</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNqFkctOwzAQRSMEElD4By_ZpPiV1xJKeUiVQMDecpxp6yqxi-0W8TN8K1MFiSUrWzN3juf6ZhlhdMooK683UxNsCrD3zkw55QLLkjFxlJ2xumpyKkt2jHcqaV5LXp9m5zFuKKVSltVZ9n3jks1f7hgJYNa678GtgFhHjB9a63Sy3pFPm9ZEH4TaraxfgYNoI_FhLM4f7l8JrqDTAC6RFr6868g2-FWAGA8A5CF-FwL2rwdIOiYkG-J09Nu1Dl_4qO6J0cFY5wdNtthGbbzITpa6j3D5e06yt_v5--wxXzw_PM1uFrmRlKWcN00DALyiXHKhBW-XphGikBLKspOsKyvWFiUVbdFwUTDBdFMbxoq6ElUjJtnVSMWdP3YQkxpsNND32oHfRcXroqoLIThFaT1KTfAxBliqbbADOlCMqkMgaqP-AlGHQNQYCI7ejqOARvYWgooGTRroLH5OUp23_0N-AOYInGY</recordid><startdate>202310</startdate><enddate>202310</enddate><creator>Jiang, Yaofei</creator><creator>Fang, Ting</creator><creator>Lu, Nian</creator><creator>Bei, Weixin</creator><creator>Dong, Shuhui</creator><creator>Xia, Weixiong</creator><creator>Liang, Hu</creator><creator>Xiang, Yanqun</creator><general>Elsevier B.V</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202310</creationdate><title>Anti-PD1 rechallenge in combination with anti-angiogenesis or anti-EGFR treatment beyond progression in recurrent/metastatic nasopharyngeal carcinoma patients</title><author>Jiang, Yaofei ; Fang, Ting ; Lu, Nian ; Bei, Weixin ; Dong, Shuhui ; Xia, Weixiong ; Liang, Hu ; Xiang, Yanqun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c401t-2999eee2702423a32bfc933544e66d41d671b5603b59235131a98c115873793</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Anti-angiogenesis</topic><topic>EGFR inhibitors</topic><topic>Nasopharyngeal carcinoma</topic><topic>PD1 inhibitors</topic><topic>Prognosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jiang, Yaofei</creatorcontrib><creatorcontrib>Fang, Ting</creatorcontrib><creatorcontrib>Lu, Nian</creatorcontrib><creatorcontrib>Bei, Weixin</creatorcontrib><creatorcontrib>Dong, Shuhui</creatorcontrib><creatorcontrib>Xia, Weixiong</creatorcontrib><creatorcontrib>Liang, Hu</creatorcontrib><creatorcontrib>Xiang, Yanqun</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Critical reviews in oncology/hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jiang, Yaofei</au><au>Fang, Ting</au><au>Lu, Nian</au><au>Bei, Weixin</au><au>Dong, Shuhui</au><au>Xia, Weixiong</au><au>Liang, Hu</au><au>Xiang, Yanqun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anti-PD1 rechallenge in combination with anti-angiogenesis or anti-EGFR treatment beyond progression in recurrent/metastatic nasopharyngeal carcinoma patients</atitle><jtitle>Critical reviews in oncology/hematology</jtitle><date>2023-10</date><risdate>2023</risdate><volume>190</volume><spage>104113</spage><pages>104113-</pages><artnum>104113</artnum><issn>1040-8428</issn><issn>1879-0461</issn><eissn>1879-0461</eissn><abstract>We aim to evaluate the efficacy and safety of anti-PD1 rechallenge in combination with anti-angiogenesis or anti-EGFR treatment in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC) patients who progressed to previous anti-PD1 therapy. Enrolled patients were divided into a combination group and a chemotherapy only group. A total of 145 patients were enrolled. The median progress-free survival (mPFS) was 7.9 months and 4.4 months, respectively for the two groups. The combination group exhibited significantly longer PFS (HR=0.363, p < 0.001), and better disease control ratio (DCR, p = 0.022) compared with the chemotherapy group. Among the combination group, longer PFS was found in those patients who received different PD1 inhibitor from prior therapy, reached object response rate (ORR) from prior anti-PD1 therapy, and EBV DNA ≤ 1500 copy/ml before therapy, comparing to the corresponding other patients. R/M NPC patients who progressed from prior anti-PD1 therapy could benefit from the anti-PD1 rechallenge in combination with anti-angiogenesis or anti-EGFR agents.
[Display omitted]
•R/M NPC patients who progressed from prior anti-PD1 therapy could benefit from the anti-PD1 rechallenge combination therapy.•Adverse reactions of the combination therapy were tolerable.•Those who reached ORR from prior anti-PD1 therapy, EBV DNA ≤ 1500 copy/ml, and got different PD1 inhibitor, benefit more.</abstract><pub>Elsevier B.V</pub><doi>10.1016/j.critrevonc.2023.104113</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1040-8428 |
| ispartof | Critical reviews in oncology/hematology, 2023-10, Vol.190, p.104113, Article 104113 |
| issn | 1040-8428 1879-0461 1879-0461 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2857853320 |
| source | Elsevier ScienceDirect Journals |
| subjects | Anti-angiogenesis EGFR inhibitors Nasopharyngeal carcinoma PD1 inhibitors Prognosis |
| title | Anti-PD1 rechallenge in combination with anti-angiogenesis or anti-EGFR treatment beyond progression in recurrent/metastatic nasopharyngeal carcinoma patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T18%3A42%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anti-PD1%20rechallenge%20in%20combination%20with%20anti-angiogenesis%20or%20anti-EGFR%20treatment%20beyond%20progression%20in%20recurrent/metastatic%20nasopharyngeal%20carcinoma%20patients&rft.jtitle=Critical%20reviews%20in%20oncology/hematology&rft.au=Jiang,%20Yaofei&rft.date=2023-10&rft.volume=190&rft.spage=104113&rft.pages=104113-&rft.artnum=104113&rft.issn=1040-8428&rft.eissn=1879-0461&rft_id=info:doi/10.1016/j.critrevonc.2023.104113&rft_dat=%3Cproquest_cross%3E2857853320%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2857853320&rft_id=info:pmid/&rft_els_id=S1040842823002019&rfr_iscdi=true |